
Goodrays has diversified with the launch of its first non-CBD drinks range.
The brand has introduced Re:Focus, a functional blend containing lion’s mane, magnesium and electrolytes.
Cans in Zesty Lime & Kiwi and Wild Berry Mix have launched via DTC and in Waitrose, Morrisons and “other select retailers” (rsp: £7.50/4x330ml).
The drinks, which contain no added sugar or artificial ingredients, were “designed to help reset the body and focus the mind,” said Goodrays.
Goodrays’ Re:Focus drinks contained “twice the amount of magnesium and lion’s mane to other similar drinks available on the market”, the supplier claimed.
Each 330ml can contains 800mg of magnesium, 250mg of lion’s mane and 530mg of electrolytes including potassium, magnesium, calcium and sodium.
“Re:Focus is a milestone moment for us and is a first-to-market product in the UK due to the effective doses of magnesium, lion’s mane and electrolytes included,” said Goodrays founder Eoin Keenan. “We believe that functionality should never come at the cost of flavour, which is why delivering delicious taste remains at the heart of everything we create.
It comes after CBD category leader Trip debuted a Mindful Blend containing lion’s mane, magnesium and ashwaganda last spring. Sales of Trip’s Mindful Blend products now exceed those of its CBD drinks, oils and gummies.
CBD products are still not fully authorised for sale in the UK thanks to their status as novel foods.
Their sale is permitted provided they are linked to a novel foods application with the FSA, but until recently products could not be reformulated and new brands and flavours could not be launched.
In July, the FSA said it would allow products to be reformulated in line with evidence published by its independent scientific committee on CBD.
The change would “make it easier for businesses to align with the updated guidance” and “give consumers access to more CBD products that meet the FSA’s advised limits,” the FSA said.
The ACI for CBD was reduced from 70mg a day to just 10mg in October 2023.






No comments yet